Find a Trial Find Expert Physicians 
News Trial Stats
Clinical TrialsFacts & Fears Who pays for it, placebos, being a guinea pig, and what taking part really means.Basics ofTheranostics A fundamental way of finding and treating your cancer, all in one.Basics ofRadiation What is radiation, and how can it benefit you? InterpretingYour Scans What CT, MRI and PET can and can’t tell you about cancer.What to Expect as aTheranostic Patient Scans, treatment day, and the precautions once you are home.Basics ofDosimetry How much radiation each organ and tumor actually absorbs.TheranosticDictionary Plain-language meanings for the vocabulary on your paperwork.
News Trial StatsDark mode
Contact XCancer®
Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT05499936
68Ga-FAPI PET/CT for the Detection of Adenoid Cystic Carcinoma(ACC)
Overview
This study was used to study the diagnostic value of 68Ga-FAPI, a novel fibroblast activating inhibitor, in metastatic adenoid cystic carcinoma（ACC）
Phase
N/A
Contacts
Zhaohui Zhu (CONTACT)
Rongxi Wang (CONTACT)
pumch_jacobwong@163.com
+8619800370331
Zhaohui Zhu (STUDY_CHAIR)
ClinicalTrials.gov
NCT05499936Drug / Compound
FAPI
Isotope(s):
GALLIUM-68
Radioisotope: Ga-68
Theranostic Role: PET Imaging
T1/2 (Half-Life): 68 minutes
Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
Range: N/A
Decay Daughters: Zn68 (Stable)
Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
Target(s):
- FAP
Ligand Class: Small Molecules
Chelator: DOTA
Eligibility
Inclusion
Inclusion criteria not yet provided.
Exclusion
- claustrophobia, pregnancy, breastfeeding, kidney or liver failure, inability to fulfill the study
Share your feedback
Help us improve your experience